The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats
TNBG-5602, a novel anticancer drug candidate, may induce the expression of PPARγ, causing targeted lipotoxicity in cancer tissues. In this study, the in vivo metabolism in rats, in vitro metabolism in recombinant cytochromes, molecular docking for the CYP binding site, and pharmacokinetics in rats w...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/27/8/2594 |
| _version_ | 1797409885232562176 |
|---|---|
| author | Rui Li Sha Zhou Zongjie Gan Lijuan Wang Yu Yu |
| author_facet | Rui Li Sha Zhou Zongjie Gan Lijuan Wang Yu Yu |
| author_sort | Rui Li |
| collection | DOAJ |
| description | TNBG-5602, a novel anticancer drug candidate, may induce the expression of PPARγ, causing targeted lipotoxicity in cancer tissues. In this study, the in vivo metabolism in rats, in vitro metabolism in recombinant cytochromes, molecular docking for the CYP binding site, and pharmacokinetics in rats were explored to better understand TNBG-5602′s in vivo fate and behavior. Thirteen metabolites were identified using a high-resolution mass spectrometry method, and metabolizing pathways of TNBG-5602 were proposed. Results suggest that TNBG-5602 could be metabolized by CYP450s, while CYP2D6 may play an important role in its in vivo metabolism. The main metabolizing sites of TNBG-5602 are the amino group on the side chain and rings A and E in the molecule. TNBG-5602 is a potent CYP2D6 inhibitor, with an IC<sub>50</sub> value of 2.52 μM. An interaction responsible for its metabolism is formed by the NH on the side chain bonding with the ASP301 on the CYP2D6. The pharmacokinetics in rats after a single intravenous administration were fitted to a two-compartment model. The clearance was 0.022 L min<sup>−1</sup>, and the elimination half-life was 710.9 min. The distribution volume of the peripheral compartment was 1.88-fold that of the central compartment, while the K<sub>12</sub> was 1.5-fold that of K<sub>21</sub>. In conclusion, these studies have not only revealed the metabolizing pathways of TNBG-5602 using in vivo and in vitro methodology, but they have also provided the pharmacokinetic characteristics of TNBG-5602 in rats. The results suggest that TNBG-5602 has good drug developability in terms of pharmacokinetic behaviors. |
| first_indexed | 2024-03-09T04:20:57Z |
| format | Article |
| id | doaj.art-726bca18e3e34b0895d0056d91190524 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T04:20:57Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-726bca18e3e34b0895d0056d911905242023-12-03T13:47:04ZengMDPI AGMolecules1420-30492022-04-01278259410.3390/molecules27082594The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in RatsRui Li0Sha Zhou1Zongjie Gan2Lijuan Wang3Yu Yu4College of Pharmacy, Chongqing Medical University, Chongqing 400016, ChinaYaopharma Co., Ltd., Chongqing 401121, ChinaCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, ChinaDepartment of Pharmaceutics, Chongqing Engineering Research Center of Pharmaceutical Sciences, Chongqing Medical and Pharmaceutical College, Chongqing 401331, ChinaCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, ChinaTNBG-5602, a novel anticancer drug candidate, may induce the expression of PPARγ, causing targeted lipotoxicity in cancer tissues. In this study, the in vivo metabolism in rats, in vitro metabolism in recombinant cytochromes, molecular docking for the CYP binding site, and pharmacokinetics in rats were explored to better understand TNBG-5602′s in vivo fate and behavior. Thirteen metabolites were identified using a high-resolution mass spectrometry method, and metabolizing pathways of TNBG-5602 were proposed. Results suggest that TNBG-5602 could be metabolized by CYP450s, while CYP2D6 may play an important role in its in vivo metabolism. The main metabolizing sites of TNBG-5602 are the amino group on the side chain and rings A and E in the molecule. TNBG-5602 is a potent CYP2D6 inhibitor, with an IC<sub>50</sub> value of 2.52 μM. An interaction responsible for its metabolism is formed by the NH on the side chain bonding with the ASP301 on the CYP2D6. The pharmacokinetics in rats after a single intravenous administration were fitted to a two-compartment model. The clearance was 0.022 L min<sup>−1</sup>, and the elimination half-life was 710.9 min. The distribution volume of the peripheral compartment was 1.88-fold that of the central compartment, while the K<sub>12</sub> was 1.5-fold that of K<sub>21</sub>. In conclusion, these studies have not only revealed the metabolizing pathways of TNBG-5602 using in vivo and in vitro methodology, but they have also provided the pharmacokinetic characteristics of TNBG-5602 in rats. The results suggest that TNBG-5602 has good drug developability in terms of pharmacokinetic behaviors.https://www.mdpi.com/1420-3049/27/8/2594TNBG-5602metabolismbiotransformation pathwaymolecular dockingpharmacokineticsIC<sub>50</sub> |
| spellingShingle | Rui Li Sha Zhou Zongjie Gan Lijuan Wang Yu Yu The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats Molecules TNBG-5602 metabolism biotransformation pathway molecular docking pharmacokinetics IC<sub>50</sub> |
| title | The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats |
| title_full | The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats |
| title_fullStr | The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats |
| title_full_unstemmed | The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats |
| title_short | The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats |
| title_sort | biological fate of a novel anticancer drug candidate tnbg 5602 metabolic profile interaction with cyp450 and pharmacokinetics in rats |
| topic | TNBG-5602 metabolism biotransformation pathway molecular docking pharmacokinetics IC<sub>50</sub> |
| url | https://www.mdpi.com/1420-3049/27/8/2594 |
| work_keys_str_mv | AT ruili thebiologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats AT shazhou thebiologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats AT zongjiegan thebiologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats AT lijuanwang thebiologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats AT yuyu thebiologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats AT ruili biologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats AT shazhou biologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats AT zongjiegan biologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats AT lijuanwang biologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats AT yuyu biologicalfateofanovelanticancerdrugcandidatetnbg5602metabolicprofileinteractionwithcyp450andpharmacokineticsinrats |